TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01800253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory task
Description: Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory task
Description: Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue samples
Description: Expression profiles will be analyzed from samples obtained from tissues involved in metabolism

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue samples
Description: Expression profiles will be analyzed from samples obtained from tissues involved in metabolism

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: 75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: 75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Task
Description: Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Task
Description: Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
Study: NCT04292236

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lauric Acid, Perilla Oil and Diindolylmethane
Description: Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lauric Acid, Perilla Oil and Diindolylmethane
Description: Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
Study: NCT00754741

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence information
Description: Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence information plus motivational interviewing
Description: Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
Study: NCT03042546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Sulfate
Description: Calcium Sulfate with abx will be used in the defect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PMMA
Description: PMMA with abx will be used in the defect

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: The defect will not be treated
Study: NCT02576600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videopupillometer Algiscan
Description: pupillary diameter measurement every five minutes per-operatively

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard practice
Description: remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: TCI
Study: NCT02948673

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutathione
Description: 4 oral GSH tablets/day (1000mg/day) for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 oral placebo tablets for 4 weeks
Study: NCT01127152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measure of arterial pressure
Description: Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measure of arterial pressure
Description: Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
Study: NCT04542889

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Absolute coronary flow and resistance measurements
Description: Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMR measurement
Description: IMR measurement by thermodilution using the St Jude pressure guide.
Study: NCT03293004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed collagen
Description: Escalating dose of Hydrolyzed collagen

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Escalating dose of Vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimized Hydrolyzed Collagen and Vitamin C
Description: combination of optimized doses of Hydrolyzed Collagen and Vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gummy Placebo
Description: Gummy placebo
Study: NCT00477659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Description: Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks
Study: NCT04059302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy for Insomnia
Description: The therapy consists of 6 modules or 'cores' that are introduced on a weekly basis. The cores are designed to decrease sleep-inhibiting cognitions and behaviors, and to alter sleep-wake schedules.
Study: NCT01967589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Once-daily doses for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Once-daily doses for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Once-daily doses for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Once-daily doses for oral administration
Study: NCT03881176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject
Study: NCT03302078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Fasted state
Study: NCT02601976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT03472716

Intervention type: PROCEDURE
Intervention: Biological Samples
Description: 5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy).~In case of relapse, new samples will be performed (blood and tumoral samples)
Study: NCT04563208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered on Days 1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuACT
Description: Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
Study: NCT00876681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal catheter placed via ultrasound or electrical stimulation
Description: Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal catheter placed via ultrasound or electrical stimulation
Description: Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
Study: NCT01131182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Sulfonylurea
Description: Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants could continue pre-study metformin as concomitant therapy during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants could continue pre-study metformin as concomitant therapy during the study.
Study: NCT03466073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Plasma Gelsolin
Description: Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Plasma Gelsolin
Description: Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Plasma Gelsolin
Description: Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Plasma Gelsolin
Description: Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline in volume equivalent to drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline in volume equivalent to drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline in volume equivalent to drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline in volume equivalent to drug
Study: NCT04012476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
Study: NCT00744757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
Study: NCT02576600

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: TCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: TCI

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Remifentanil
Description: TCI
Study: NCT02983123

Intervention type: PROCEDURE
Intervention: 1-hour hs-cTnT
Study: NCT03889132

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
Study: NCT02971826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIVETM SE thrombectomy
Description: Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
Study: NCT04663113

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group/1st group ( standard physiotherapy
Description: It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2nd group- Standard physiotherapy + bicycle ergometer
Description: Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3rd group- Standard physiotherapy + exercise protocol to be developed
Description: Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.~Portable indirect calorimetry will be used to measure the basal metabolic rates of the patients.~The basal metabolic rates of the patients will be measured before the exercise and aerobic exercise or resistant exercise will be given according to the metabolic state of the patient.~Ratings of perceived exertion (RPE) will be used as the aerobic exercise protocol and a 10-11 strength exercise will be given according to the RPE.~If resistance exercise will be given, the intensity of the exercise (12-14) will be determined according to the RPE. Sandbags attached to the ankle will be used as a resistance exercise and 9 exercises were determined. (Knee extension, knee flexion, trunk flexion, trunk extension, hip extension, hip flexion, hip abduction, shoulder flexion, shoulder abduction
Study: NCT02637596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
Study: NCT02757196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus methylprednisolone
Description: rituximab （1000mg IV day1, week 3, week 17 , and week 19）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
Study: NCT03344471

Intervention type: OTHER
Group type: OTHER
Intervention: Passation of questionnaires
Description: Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
Study: NCT03534284

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: trazodone tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill manufactured to mimic trazodone tablets.
Study: NCT04685954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Bulk-Fill Posterior
Description: Bulk-fill restorative composite

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Ultimate Universal
Description: Incremental restorative composite
Study: NCT04562909

Intervention type: DEVICE
Intervention: Neurocom balance master device
Description: With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.

Intervention type: DEVICE
Intervention: Neurocom balance master device
Description: With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
Study: NCT03979066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
Study: NCT02332603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study: NCT00623181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone: Influenza virus vaccine
Description: 0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone: Influenza virus vaccine
Description: 0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
Study: NCT00492102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing \>1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.